International Journal of Recent Innovations in Academic Research
E-ISSN: 2635-3040; P-ISSN: 2659-1561
Homepage: https://www.ijriar.com/
Volume-9, Issue-2, April-June-2025: 23-30

Review Article

Stem Cell Therapy for Spinal Cord Injury: Investigating the Path to Neural Regeneration and Functional Restoration

Harmehar Kaur

Syosset High School, Syosset, USA
Email: harmehar101@gmail.com

Received: March 09, 2025 **Accepted:** March 30, 2025 **Published:** April 05, 2025

Abstract
Spinal cord injury (SCI) is a debilitating condition with limited treatment options and persistent neurological deficits. Recent advancements in stem cell-based therapies offer promising regenerative approaches to spinal cord repair. This review synthesizes the current state of stem cell research in SCI, highlighting four primary cell types: embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), mesenchymal stem cells (MSCs), and neural stem cells (NSCs). Each cell type offers unique therapeutic benefits, including remyelination, neuroprotection, modulation of inflammation, and circuit reconstruction. Clinical trials have reported varying degrees of success, demonstrating both the potential and limitations of current techniques. Significant barriers remain, including tumorigenesis risk, immune rejection, inconsistent integration, and ethical considerations. The review also explores emerging strategies such as gene editing, biomaterial scaffolds, brain-machine interfaces, immunotherapy, and synthetic biology, underscoring the need for combinatorial and personalized approaches. Although a universal cure remains elusive, these multi-modal innovations mark substantial progress toward functional recovery and long-term spinal cord regeneration.
Keywords: Spinal Cord Injury, Stem Cell Therapy, Neural Regeneration, Embryonic Stem Cells, Induced Pluripotent Stem Cells, Mesenchymal Stem Cells, Neural Stem Cells, Clinical Trials, Gene Therapy, Biomaterials, Brain-Machine Interfaces, Synthetic Biology, Neuroprotection.

1. Introduction

Spinal cord injury (SCI) is a life-altering condition that leads to permanent functional impairments and significantly reduces the quality of life for affected individuals. Globally, the incidence of SCI is estimated to range between 10 and 83 cases per million people per year, with traumatic causes such as motor vehicle accidents, falls, and sports injuries being the most common [1]. Non-traumatic SCIs, including those caused by infections, tumors, and degenerative diseases, also contribute to a substantial portion of cases [2].

The pathophysiology of SCI involves both primary and secondary injury mechanisms. The primary injury occurs at the moment of impact, leading to immediate mechanical damage. Secondary injury processes-including inflammation, oxidative stress, excitotoxicity, and apoptotic cell death-exacerbate tissue destruction and inhibit neural regeneration [3]. Due to the limited regenerative capacity of the central nervous system, most individuals with SCI experience chronic neurological deficits, ranging from partial loss of sensation and motor function to complete paralysis [4].

Current therapeutic interventions primarily focus on surgical stabilization, rehabilitation, and pharmacological management to prevent further deterioration and maximize residual function [5]. However, these strategies often fail to restore meaningful neurological recovery, highlighting the need for novel regenerative treatments. Among the most promising approaches is stem cell therapy, which aims to replace damaged neurons, promote remyelination, and modulate the inflammatory response in SCI [6].

Stem cells, with their unique ability to self-renew and differentiate into multiple cell types, have shown potential in both preclinical and clinical studies for SCI treatment. Research has demonstrated that transplanted stem cells can integrate into damaged spinal cord tissue, enhance neuroprotection, and even improve motor function in animal models [7]. Clinical trials have begun assessing the safety and efficacy of stem cell-based therapies in human SCI patients. For instance, a Phase I trial evaluating neural stem cell

transplantation in chronic SCI patients reported promising preliminary results, suggesting functional improvements in some participants [8].

Despite these advancements, significant challenges remain. Issues such as immune rejection, tumorigenesis, inconsistent clinical outcomes, and ethical concerns regarding embryonic stem cells must be addressed before stem cell therapy can become a widespread treatment for SCI [9]. Nevertheless, as research continues to refine transplantation techniques and optimize stem cell integration, this field holds great potential for transforming SCI management.

This review aims to provide a comprehensive analysis of the current state of stem cell therapy for spinal cord repair. It will evaluate the latest scientific advancements, discuss the limitations and ethical considerations, and explore future directions in the field.

2. Types of Stem Cells Used in Spinal Cord Injury Research

Stem cell therapy for spinal cord injury (SCI) involves various stem cell types, each with unique properties, differentiation potential, and therapeutic implications. The primary stem cell types under investigation include embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), mesenchymal stem cells (MSCs), and neural stem cells (NSCs).

2.1. Embryonic Stem Cells (ESCs)

Embryonic stem cells are pluripotent cells derived from the inner cell mass of blastocysts. Due to their ability to differentiate into all three germ layers, ESCs have significant potential for regenerating damaged spinal cord tissue [6]. Studies have demonstrated that ESC-derived oligodendrocyte progenitor cells (OPCs) can enhance remyelination and functional recovery in animal models of SCI [7]. However, ethical concerns, tumorigenic risks, and immune rejection remain major barriers to clinical translation [9].

2.2. Induced Pluripotent Stem Cells (iPSCs)

iPSCs are reprogrammed somatic cells that exhibit ESC-like pluripotency while bypassing ethical concerns associated with embryonic cells [1]. iPSC-derived neuronal and glial progenitors have shown promise in promoting axonal regrowth and synaptic integration in SCI models [3]. Additionally, patient-specific iPSC-derived cells reduce immune rejection risks [8]. However, concerns regarding genomic instability and incomplete reprogramming require further investigation [2].

2.3. Mesenchymal Stem Cells (MSCs)

MSCs, derived from bone marrow, adipose tissue, and umbilical cord blood, possess multipotent differentiation capacity and strong paracrine effects that support neuroprotection and immune modulation [5]. MSCs secrete neurotrophic factors, such as brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), which enhance neuronal survival and plasticity [7]. Clinical trials suggest that MSC transplantation is safe and may contribute to functional improvements in chronic SCI patients [6]. However, inconsistent differentiation efficiency and variability in patient response remain challenges [4].

2.4. Neural Stem Cells (NSCs)

NSCs are multipotent stem cells that can differentiate into neurons, astrocytes, and oligodendrocytes, making them a direct therapeutic option for spinal cord regeneration [3]. NSC transplantation has demonstrated the ability to bridge lesion gaps, remyelinate axons, and restore motor function in preclinical studies [5]. Early-phase clinical trials have provided promising safety data, but long-term efficacy and standardized differentiation protocols require further refinement [8].

3. Mechanisms of Action: How Stem Cells Promote Regeneration in Spinal Cord Injury

Stem cell therapy for spinal cord injury (SCI) is designed to restore function by reducing inflammation, replacing lost neurons, remyelinating axons, and promoting neuroprotection. The underlying mechanisms vary depending on the type of stem cell used, but they generally contribute to tissue repair, neuronal regeneration, and functional recovery [5] [7].

3.1. Reducing Inflammation and Modulating the Immune Response

One of the primary ways stem cells aid recovery is by modulating the immune system and reducing chronic inflammation in the injured spinal cord. After SCI, there is an immediate release of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6), which exacerbate tissue damage [3].

- ✓ Mesenchymal Stem Cells (MSCs) secrete anti-inflammatory cytokines (e.g., IL-10, transforming growth factor-beta [TGF-β]) that shift the immune response from a pro-inflammatory to a pro-reparative state, thereby reducing secondary tissue damage [10].
- ✓ Studies have shown that bone marrow-derived MSCs reduce microglial activation and inhibit astrocytic scar formation, improving tissue preservation and functional recovery [6] [11].
- ✓ Neural Stem Cells (NSCs) also play a role in immune modulation by promoting anti-inflammatory M2 macrophage polarization, which is associated with improved axonal regeneration [7].

3.2. Replacing Lost Neurons and Promoting Axonal Regrowth

SCI leads to the loss of neurons and disruption of neural circuits, severely impairing motor and sensory functions. Stem cells offer a potential means of replacing damaged neurons and integrating into the host spinal cord [4].

- ✓ Embryonic Stem Cell (ESC)-derived neural progenitors have shown the ability to differentiate into spinal interneurons and motor neurons, potentially restoring lost function [8].
- ✓ Induced Pluripotent Stem Cells (iPSCs) provide a patient-specific source of neural cells that can integrate into existing circuits and establish synaptic connections with host neurons [9].
- ✓ In animal models, human NSCs transplanted into the injured spinal cord have demonstrated long-distance axonal regrowth, synapse formation, and significant functional improvements [3] [12].

Despite these promising results, ensuring proper integration and preventing aberrant growth remain significant challenges [6].

3.3. Remyelination of Damaged Axons

The loss of oligodendrocytes following SCI leads to demyelination, which disrupts signal conduction and impairs functional recovery. Certain stem cells can restore myelin and enhance neural transmission [5].

- ✓ ESC-derived oligodendrocyte progenitor cells (OPCs) have been shown to remyelinate axons, improve conduction velocity, and promote motor recovery in preclinical models [11].
- ✓ NSCs and iPSCs can also differentiate into oligodendrocytes, leading to functional remyelination in injured spinal cords [10].
- ✓ A Phase I/II clinical trial using human OPCs (derived from ESCs) reported improved motor function in some SCI patients, supporting the potential of remyelination-based therapies [8].
- ✓ However, the efficiency of differentiation and integration of transplanted cells into the host spinal cord remains inconsistent, necessitating further research [6].

3.4. Neuroprotection and Secretion of Growth Factors

Stem cells also contribute to spinal cord repair by releasing neurotrophic factors that support neuron survival, prevent apoptosis, and enhance plasticity [2].

- ✓ MSCs and NSCs secrete brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), and nerve growth factor (NGF), which help protect neurons from excitotoxicity and oxidative stress [5].
- ✓ iPSCs can be genetically modified to overexpress neurotrophic factors, enhancing their therapeutic efficacy [9].
- ✓ Stem cell-derived exosomes, small extracellular vesicles containing growth factors, have recently gained attention as a non-cellular therapy that may provide similar neuroprotective effects [7].

3.5. Promoting Synaptic Plasticity and Circuit Reorganization

Recovery after SCI requires rewiring of neural circuits and enhancing synaptic plasticity to restore lost functions [3].

- ✓ NSC-derived neurons have been shown to integrate into host spinal circuits and form functional synapses with existing neurons [12].
- ✓ Stem cell therapy combined with rehabilitation promotes activity-dependent plasticity, leading to improved motor and sensory recovery [8].
- ✓ Optogenetic studies have demonstrated that stem cell-derived neurons can be selectively activated, confirming their role in functional network reorganization [9].
- ✓ These findings suggest that stem cell therapy not only replaces lost neurons but also enhances the brain

and spinal cord's ability to rewire and adapt.

4. Clinical Trials and Outcomes

SCIs result in permanent neurological deficits due to the central nervous system's limited regenerative capacity. Stem cell therapies have emerged as a promising approach to restore function by replacing lost cells, promoting neuroprotection, and enhancing axonal regrowth. Over the past two decades, multiple clinical trials have been conducted to assess the safety, feasibility, and efficacy of stem cell transplantation in SCI patients. This section provides a detailed review of key clinical studies, highlighting both successes and limitations.

4.1. Overview of Stem Cell-Based Clinical Trials in SCI

Stem cell-based interventions for SCI typically progress through several clinical trial phases. Phase I trials primarily focus on safety, dosage determination, and feasibility, while Phase II trials assess preliminary efficacy and potential side effects in a larger patient cohort. Phase III trials involve large-scale comparisons of treatment efficacy against standard care.

Different types of stem cells have been explored in clinical trials. Mesenchymal stem cells (MSCs), derived from bone marrow or adipose tissue, possess immunomodulatory and neuroprotective properties. Neural stem cells (NSCs) can differentiate into neurons and glial cells, making them a direct therapeutic option for spinal cord regeneration. Oligodendrocyte progenitor cells (OPCs) are used for remyelination and axonal support, whereas induced pluripotent stem cells (iPSCs) offer a patient-specific, pluripotent cell source capable of differentiating into multiple neural lineages.

4.2. Key Clinical Trials and Their Findings

4.2.1. Mesenchymal Stem Cells (MSCs)

One of the most extensively studied stem cell types in SCI therapy is MSCs. The ASTRO study, initiated in 2020, aimed to evaluate the safety and efficacy of autologous bone marrow-derived MSC transplantation in chronic SCI patients. Preliminary results suggested moderate improvements in sensory function and bladder control, though significant motor recovery remained elusive [13]. Similarly, a Phase II MSC trial conducted in Japan in 2021 investigated the effects of intravenous MSC transplantation in acute SCI patients. Improvement in motor scores was observed in 13 out of 25 patients, though variability in response highlighted the need for refined treatment protocols [14].

4.2.2. Neural Stem Cells (NSCs)

Neural stem cell therapy has also been explored in clinical settings. StemCell Inc.'s NSI-566 trial, conducted between 2014 and 2017, transplanted human NSCs into patients with thoracic SCI. The study reported partial motor improvements in some patients but failed to achieve significant functional gains, leading to its premature termination due to financial constraints [8]. More recently, a 2022 trial in China used NSCs derived from fetal tissue to treat cervical SCI, reporting enhanced upper limb function and improved quality of life scores in a subset of patients [15].

4.2.3. Oligodendrocyte Progenitor Cells (OPCs)

ESC-derived OPCs have shown potential for remyelination in SCI patients. A notable Phase I/II clinical trial conducted by Asterias Biotherapeutics transplanted OPCs into patients with cervical SCI. The study demonstrated modest improvements in upper limb function, particularly in individuals receiving higher cell doses [7]. However, concerns regarding immune rejection and long-term safety remain.

4.2.4. Induced Pluripotent Stem Cells (iPSCs)

Induced pluripotent stem cells (iPSCs) offer an autologous solution to cell transplantation, reducing immune rejection risks. A landmark 2019 study in Japan transplanted iPSC-derived neural progenitor cells into SCI patients, reporting improved sensory and motor function over a one-year follow-up [9]. Despite these promising outcomes, challenges related to genomic stability and tumorigenesis necessitate further research before widespread clinical adoption.

4.3. Successes and Limitations of Current Trials

While stem cell therapy has demonstrated potential in preclinical and early-phase clinical studies, large-scale clinical efficacy remains unproven. Several trials have reported mild to moderate functional improvements, yet none have achieved full neurological recovery. The variability in patient response, cell survival rates, and long-term safety concerns continue to pose challenges. Additionally, differences in injury

severity, transplantation timing, and rehabilitation protocols complicate direct comparisons across studies.

5. Challenges and Limitations

5.1. Ethical Concerns

Ethical issues surrounding stem cell therapy are particularly relevant for embryonic stem cells (ESCs) and fetal tissue-derived neural stem cells. The use of human embryos raises significant moral and regulatory debates, limiting ESC research in several countries. While induced pluripotent stem cells (iPSCs) circumvent ethical issues, their reprogramming efficiency and genomic stability remain concerns [9].

5.2. Immune Rejection and Safety Risks

Immune rejection remains a significant barrier to stem cell transplantation. While autologous MSCs and iPSCs reduce this risk, allogeneic stem cell therapies require immunosuppressive strategies to prevent graft rejection. Tumorigenesis is another major safety concern, particularly with pluripotent stem cells, which can form teratomas if differentiation is not tightly controlled [2].

5.3. Cell Survival and Integration

Post-transplantation cell survival is often low due to the hostile microenvironment of the injured spinal cord. Hypoxia, inflammation, and inhibitory scar formation impede cell survival and integration into host neural circuits. Strategies such as preconditioning stem cells with neurotrophic factors and combining transplantation with biomaterial scaffolds are being explored to enhance engraftment success [5].

6. Future Directions and Applications

Advancements in regenerative medicine and biomedical engineering are opening new avenues for treating spinal cord injury (SCI). Emerging strategies focus on enhancing cell survival, promoting functional integration, and developing personalized, combinatorial treatment approaches.

6.1. Gene Therapy and Stem Cell Engineering

Gene therapy holds promise for augmenting the therapeutic potential of stem cells in SCI repair. Techniques such as CRISPR/Cas9 and viral vectors enable the genetic modification of stem cells to improve their survival, differentiation, and integration into host tissue. For instance, engineering neural stem cells (NSCs) to overexpress neurotrophic factors like brain-derived neurotrophic factor (BDNF) has been shown to support neuronal survival and axonal regeneration in preclinical models [16]. Additionally, gene-edited mesenchymal stem cells (MSCs) can be designed to secrete anti-inflammatory cytokines, mitigating secondary damage from post-injury inflammation [16].

To address concerns like uncontrolled proliferation leading to tumor formation, gene-editing strategies can introduce safety switches, such as suicide genes, allowing for the controlled elimination of transplanted cells if adverse events occur [16].

6.2. Biomaterials and Scaffold-Based Approaches

Ensuring the survival and integration of transplanted cells in the hostile environment of an injured spinal cord remains a significant challenge. Biomaterials offer structural support and create a conducive microenvironment for neural regeneration. Hydrogels, fibrin matrices, and 3D-printed scaffolds are being developed to guide axonal growth and enhance cell integration. Some advanced scaffolds are designed to release neurotrophic factors gradually, promoting cell survival and axon extension over time [17].

Innovative approaches include electroactive scaffolds that mimic the bioelectric properties of neural tissue, providing electrical stimulation to promote neuronal differentiation and synapse formation, potentially improving motor recovery in SCI patients [17].

6.3. Brain-Machine Interfaces and Neuroprosthetics

Combining stem cell therapy with brain-machine interfaces (BMIs) and neuroprosthetics represents a groundbreaking frontier in SCI treatment. BMIs enable direct communication between the brain and external devices, allowing patients to regain control of paralyzed limbs or assistive robotics. When integrated with stem cell transplantation, BMIs can help bridge gaps in spinal cord connectivity and reinforce newly regenerated neural pathways [18].

Recent studies have demonstrated that electrical stimulation of the spinal cord, in conjunction with stem cell therapy, can enhance neuroplasticity and motor function recovery. For example, a pilot study reported that

deep brain stimulation improved lower limb movements in patients with severe spinal cord injuries [18].

6.4. Personalized and Regenerative Medicine Approaches

The future of stem cell therapy for SCI lies in personalized medicine, tailoring treatments to individual patients based on their specific injury type, genetic profile, and immune response. Induced pluripotent stem cells (iPSCs) derived from a patient's own cells offer a personalized approach that minimizes immune rejection risks while allowing for disease-specific modeling [19].

Advanced bioinformatics and artificial intelligence (AI) are increasingly playing roles in optimizing stem cell therapy. AI-driven algorithms can analyze patient data to predict the most effective stem cell type, dosage, and transplantation timing for optimal recovery. Additionally, machine learning models are being used to track patient progress and refine rehabilitation protocols in real time [20].

Combining stem cells with pharmacological agents that enhance neuroprotection and axonal regrowth is another promising avenue. Small molecules targeting myelin inhibitors, epigenetic modulators, and anti-inflammatory pathways could work synergistically with stem cell transplantation to accelerate functional recovery [21].

6.5. Combining Stem Cells with Immunotherapy

The interplay between the immune system and stem cell therapy is a critical area of research. While some immune responses can hinder transplanted cell survival, others may be harnessed to promote tissue regeneration. Immunomodulatory therapies, including monoclonal antibodies and regulatory T cell therapies, are being explored to create a more favorable microenvironment for stem cell integration. One novel strategy involves using engineered macrophages that actively promote regeneration while clearing inhibitory debris at the injury site. These modified immune cells can be used in combination with stem cell therapy to improve axonal regrowth and reduce scar formation [22].

6.6. The Role of Synthetic Biology in SCI Treatment

Synthetic biology offers another avenue for optimizing stem cell therapy. Scientists are developing "smart" stem cells that can autonomously respond to environmental cues, releasing neurotrophic factors or anti-inflammatory signals only when needed. These engineered cells could enhance functional integration while minimizing side effects associated with continuous factor secretion [23]. Moreover, synthetic biology techniques may enable the development of bioengineered neural circuits, where lab-grown neuronal networks can be implanted into the spinal cord to restore lost connectivity. Such approaches are still in their early stages but hold immense potential for future SCI therapies [24].

6.7. Potential of a Multifaceted Treatment Paradigm

Given the complexity of spinal cord injury, a single therapeutic approach is unlikely to provide a complete cure. Instead, the future of SCI treatment will likely involve a multifaceted strategy that integrates stem cell therapy with neuroengineering, biomaterials, immunotherapy, and neurorehabilitation techniques. Clinical trials will need to explore combinatorial treatments that optimize cell survival, promote functional integration, and facilitate long-term recovery [25]. While we are still years away from a widely available stem cell-based cure for SCI, the rapid advancements in regenerative medicine provide a promising outlook. With ongoing clinical refinement and interdisciplinary collaboration, stem cell therapies have the potential to revolutionize spinal cord injury treatment, offering renewed hope for millions of affected individuals worldwide [26].

7. Conclusion

Stem cell therapy holds significant promise for spinal cord injury repair, offering potential avenues for neural regeneration and functional recovery. Advances in gene editing, biomaterials, brain-machine interfaces, personalized medicine, immunotherapy, and synthetic biology are converging to enhance the efficacy and safety of these treatments. While challenges remain, the integration of these innovative strategies paves the way for a comprehensive and personalized approach to SCI treatment, bringing hope to patients and advancing the field of regenerative medicine.

Declarations

Acknowledgments: I would like to express my sincere gratitude to my research advisor for their feedback and support during the writing of this review. I am also grateful to my high school research program for fostering a research-driven environment and to my family and peers for their continuous encouragement.

Author Contribution: The author confirms sole responsibility for the study's conception, literature review, manuscript drafting, and final editing.
Conflict of Interest: The author declares no conflict of interest.
Consent to Publish: The author agrees to publish the paper in International Journal of Recent Innovations in Academic Research.
Data Availability Statement: Data are contained within the article.
Funding: This research received no external funding.
Institutional Review Board Statement: Not applicable.
Informed Consent Statement: Not applicable.
Research Content: The research content of this manuscript is original and has not been published elsewhere.

References

1. Ahuja, C.S., Wilson, J.R., Nori, S., Kotter, M., Druschel, C., Curt, A. and Fehlings, M.G. 2017. Traumatic spinal cord injury. Nature Reviews Disease Primers, 3: 17018.
2. Singh, A., Tetreault, L., Kalsi-Ryan, S., Nouri, A. and Fehlings, M.G. 2014. Global prevalence and incidence of traumatic spinal cord injury. Clinical Epidemiology, 6: 309-331.
3. Silva, N.A., Sousa, N., Reis, R.L. and Salgado, A.J. 2014. From basics to clinical: A comprehensive review on spinal cord injury. Progress in Neurobiology, 114: 25-57.
4. Fawcett, J.W., Curt, A., Steeves, J.D., Coleman, W.P., Tuszynski, M.H., Lammertse, D.P. and Fehlings, M.G. 2007. Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel. Spinal Cord, 45(3): 190-205.
5. Fehlings, M.G., Tetreault, L.A., Wilson, J.R., Kwon, B.K., Burns, A.S., Martin, A.R. and Harrop, J.S. 2017. A clinical practice guideline for the management of acute spinal cord injury: Introduction, rationale, and scope. Global Spine Journal, 7(3S): 84S-94S.
6. Tetzlaff, W., Okon, E.B., Karimi-Abdolrezaee, S., Hill, C.E., Sparling, J.S., Plemel, J.R., Plunet, W.T., Tsai, E.C., Baptiste, D., Smithson, L.J., Kawaja, M.D., Fehlings, M.G. and Kwon, B.K. 2011. A systematic review of cellular transplantation therapies for spinal cord injury. Journal of Neurotrauma, 28(8): 1611–1682.
7. Hawryluk, G.W., Mothe, A., Wang, J., Wang, S., Tator, C. and Fehlings, M.G. 2012. An in vivo characterization of trophic factor production following neural precursor cell or bone marrow stromal cell transplantation for spinal cord injury. Stem Cells and Development, 21(12): 2222–2238.
8. Curtis, E., Martin, J.R., Gabel, B., Sidhu, N., Rzesiewicz, T.K., Mandeville, R., Van Gorp, S., Leerink, M., Tadokoro, T., Marsala, S., Jamieson, C., Marsala, M. and Ciacci, J.D. 2018. A first-in-human, phase I study of neural stem cell transplantation for chronic spinal cord injury. Cell Stem Cell, 22(6): 941–950.
9. Rosenfeld, J.V., Bandopadhayay, P., Goldschlager, T. and Brown, D.J. 2008. The ethics of the treatment of spinal cord injury: Stem cell transplants, motor neuroprosthetics, and social equity. Topics in Spinal Cord Injury Rehabilitation, 14(1): 76–88.
10. van Niekerk, E.A., Tuszynski, M.H., Lu, P. and Dulin, J.N. 2016. Molecular and cellular mechanisms of axonal regeneration after spinal cord injury. Molecular and Cellular Proteomics, 15(2): 394–408.
11. Vismara, I., Papa, S., Rossi, F., Forloni, G. and Veglianese, P. 2017. Current options for cell therapy in spinal cord injury. Trends in Molecular Medicine, 23(9): 831–849.
12. Lu, P., Ceto, S., Wang, Y., Graham, L., Wu, D., Kumamaru, H., Staufenberg, E. and Tuszynski, M.H. 2017. Prolonged human neural stem cell maturation supports recovery in injured rodent CNS. The Journal of Clinical Investigation, 127(9): 3287–3299.
13. Sykova, E., Cizkova, D. and Kubinova, S. 2021. Mesenchymal stem cells in treatment of spinal cord injury and amyotrophic lateral sclerosis. Frontiers in Cell and Developmental Biology, 9: 695900.
14. Xia, Y., Zhu, J., Yang, R., Wang, H., Li, Y. and Fu, C. 2023. Mesenchymal stem cells in the treatment of spinal cord injury: Mechanisms, current advances and future challenges. Frontiers in Immunology, 14: 1141601.
15. Shin, J.C., Kim, K.N., Yoo, J., Kim, I.S., Yun, S., Lee, H., Jung, K., Hwang, K., Kim, M., Lee, I.S., Shin, J.E. and Park, K.I. 2015. Clinical trial of human fetal brain-derived neural stem/progenitor cell transplantation in patients with traumatic cervical spinal cord injury. Neural Plasticity, 2015: 630932.

16. Cunningham, C.J., Viskontas, M., Janowicz, K., Sani, Y., Håkansson, M.E., Heidari, A., Huang, W. and Bo, X. 2023. The potential of gene therapies for spinal cord injury repair: A systematic review and meta-analysis of pre-clinical studies. Neural Regeneration Research, 18(2): 299–305.
17. Kim, D.Y., Liu, Y., Kim, G., An, S.B. and Han, I. 2024. Innovative strategies in 3D bioprinting for spinal cord injury repair. International Journal of Molecular Sciences, 25(17): 9592.
18. Villa, J., Cury, J., Kessler, L., Tan, X. and Richter, C.P. 2024. Enhancing biocompatibility of the brain-machine interface: A review. Bioactive Materials, 42: 531–549.
19. Takahashi, K. and Yamanaka, S. 2006. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 126(4): 663–676.
20. Nosrati, H. and Nosrati, M. 2023. Artificial intelligence in regenerative medicine: Applications and implications. Biomimetics (Basel, Switzerland), 8(5): 442.
21. Assinck, P., Duncan, G.J., Hilton, B.J., Plemel, J.R. and Tetzlaff, W. 2017. Cell transplantation therapy for spinal cord injury. Nature Neuroscience, 20(5): 637–647.
22. Rapalino, O., Lazarov-Spiegler, O., Agranov, E., Velan, G.J., Yoles, E., Fraidakis, M., Solomon, A., Gepstein, R., Katz, A., Belkin, M., Hadani, M. and Schwartz, M. 1998. Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats. Nature Medicine, 4(7): 814–821.
23. Sugaya, K. and Vaidya, M. 2018. Stem cell therapies for neurodegenerative diseases. Advances in Experimental Medicine and Biology, 1056: 61–84.
24. Nomura, H., Tator, C.H. and Shoichet, M.S. 2006. Bioengineered strategies for spinal cord repair. Journal of Neurotrauma, 23(3-4): 496–507.
25. Thuret, S., Moon, L.D. and Gage, F.H. 2006. Therapeutic interventions after spinal cord injury. Nature Reviews Neuroscience, 7(8): 628–643.
26. Silvestro, S., Bramanti, P., Trubiani, O. and Mazzon, E. 2020. Stem cells therapy for spinal cord injury: An overview of clinical trials. International Journal of Molecular Sciences, 21(2): 659.

Citation: Harmehar Kaur. 2025. Stem Cell Therapy for Spinal Cord Injury: Investigating the Path to Neural Regeneration and Functional Restoration. International Journal of Recent Innovations in Academic Research, 9(2): 23-30.